Daiichi Sankyo Gains U.S. Diabetes Indication For Cholesterol Drug WelChol
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo received U.S. FDA sNDA approval for its cholesterol drug WelChol (colesevelam) as an adjunct therapy to improve glycemic control in patients with type 2 diabetes Jan. 18
You may also be interested in...
Daiichi Sankyo U.S. CEO Joe Pieroni: An Interview With "The Pink Sheet" DAILY (Part 1 of 2)
Daiichi Sankyo's head of U.S. operations Joe Pieroni sat down with "The Pink Sheet" DAILY recently at the firm's U.S. headquarters in Parsippany, N.J., to discuss the company's cardiovascular products and pipeline and how the Japanese pharma is looking to the U.S. market as a core growth driver. Pieroni was tapped to lead the newly formed U.S. subsidiary in 2005 following the merger of Daiichi and Sankyo. Previously, Mr. Pieroni had launched Sankyo's U.S. commercial operations, first as president of the Sankyo Parke-Davis joint venture and then as president of Sankyo Pharma Inc., a wholly owned U.S. subsidiary.
Daiichi Sankyo Submits WelChol sNDA For Diabetes Indication
If approved, WelChol would be the first LDL-lowering therapy also approved for improving glycemic control.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).